Orphalan
France - ParisBiotechnology
Focus: Orphalan is a France-based biotech company focused on small molecule treatments for rare diseases, specifically Wilson's disease. The company operates as a public entity with a highly concentrated commercial portfolio centered on a single approved product.
Profile data last refreshed 20h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
2-2 this month
Stable — net -2 jobs in 30d
2 added, 4 removed. Backfill posture.
Should You Work at Orphalan?
AI assessmentOrphalan offers stable rare-disease exposure and product revenue, but severe revenue concentration and thin hiring pipeline make it a higher-risk, lower-growth career move than larger biotech peers.
Why Work Here
- Established commercial footprint with CUVRIOR generating revenue and LOE protection until 2039, providing stable operational foundation.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$378K Part DStable
Peak12.7yr
Only approved revenue-generating product; 100% of company revenue, with patent exclusivity extending to 2039.
Help build intelligence for Orphalan
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.